Effects of 3years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis

Richard Eastell*, David M. Reid, Slobodan Vukicevic, Kristine E. Ensrud, Andrea Z. LaCroix, John R. Thompson, David D. Thompson, Steven R. Cummings

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The aims of this study were to describe the changes in bone turnover markers (BTMs) in response to lasofoxifene therapy; to describe the changes in BTMs in the individual; and to examine the relationships between BTM levels on treatment and treatment outcomes. Women (n= 1126) aged 59-80. years with femoral neck or spine bone mineral density T-scores ≤-2.5 were randomized to lasofoxifene 0.25. mg/d, 0.5. mg/d, or placebo for 5. years. We measured serum C-telopeptide of type I collagen (CTX) and serum procollagen I N-propeptide (PINP), osteocalcin, and bone alkaline phosphatase (ALP) at baseline and at 1, 3, 6, 12, 24, and 36. months. Lasofoxifene therapy resulted in a decrease in the concentrations of bone resorption and bone formation markers compared with placebo; the decrease was maximal between 6 and 24. months. The effect of lasofoxifene 0.5. mg/d was similar to that of lasofoxifene 0.25. mg/d. The decrease in bone ALP was less than the decreases in CTX, osteocalcin, and PINP. Lasofoxifene therapy 0.5. mg/d resulted in BTM-defined response rates for CTX (decrease in concentration from baseline > 60%), PINP (> 50%), and bone ALP (> 30%) of 35%, 45%, and 43% of women at month 12, respectively, compared with placebo responses of 4%, 4%, and 7%. In contrast, the increase in BMD took longer (50% responded after 36. months of lasofoxifene 0.5. mg/d) and was not as specific (15% of placebo group responded). Bone density change was weakly inversely correlated with change in the concentrations of BTMs. BTMs may prove useful in the monitoring of the response to lasofoxifene treatment for women with postmenopausal osteoporosis early in the course of treatment.

Original languageEnglish
Pages (from-to)1135-1140
Number of pages6
JournalBone
Volume50
Issue number5
Early online date11 Feb 2012
DOIs
Publication statusPublished - 1 May 2012

Fingerprint

Postmenopausal Osteoporosis
Bone Remodeling
Procollagen
Placebos
Alkaline Phosphatase
Bone and Bones
Osteocalcin
Therapeutics
Bone Density
Lasofoxifene
Femur Neck
Bone Resorption
Collagen Type I
Serum
Osteogenesis
Spine

Keywords

  • Bone turnover marker
  • Clinical trial
  • Osteoporosis
  • Treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Histology

Cite this

Eastell, R., Reid, D. M., Vukicevic, S., Ensrud, K. E., LaCroix, A. Z., Thompson, J. R., ... Cummings, S. R. (2012). Effects of 3years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. Bone, 50(5), 1135-1140. https://doi.org/10.1016/j.bone.2012.02.004

Effects of 3years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. / Eastell, Richard; Reid, David M.; Vukicevic, Slobodan; Ensrud, Kristine E.; LaCroix, Andrea Z.; Thompson, John R.; Thompson, David D.; Cummings, Steven R.

In: Bone, Vol. 50, No. 5, 01.05.2012, p. 1135-1140.

Research output: Contribution to journalArticle

Eastell, R, Reid, DM, Vukicevic, S, Ensrud, KE, LaCroix, AZ, Thompson, JR, Thompson, DD & Cummings, SR 2012, 'Effects of 3years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis', Bone, vol. 50, no. 5, pp. 1135-1140. https://doi.org/10.1016/j.bone.2012.02.004
Eastell, Richard ; Reid, David M. ; Vukicevic, Slobodan ; Ensrud, Kristine E. ; LaCroix, Andrea Z. ; Thompson, John R. ; Thompson, David D. ; Cummings, Steven R. / Effects of 3years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. In: Bone. 2012 ; Vol. 50, No. 5. pp. 1135-1140.
@article{f1d6ed75eb7c49f380857911b0d4e5e0,
title = "Effects of 3years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis",
abstract = "The aims of this study were to describe the changes in bone turnover markers (BTMs) in response to lasofoxifene therapy; to describe the changes in BTMs in the individual; and to examine the relationships between BTM levels on treatment and treatment outcomes. Women (n= 1126) aged 59-80. years with femoral neck or spine bone mineral density T-scores ≤-2.5 were randomized to lasofoxifene 0.25. mg/d, 0.5. mg/d, or placebo for 5. years. We measured serum C-telopeptide of type I collagen (CTX) and serum procollagen I N-propeptide (PINP), osteocalcin, and bone alkaline phosphatase (ALP) at baseline and at 1, 3, 6, 12, 24, and 36. months. Lasofoxifene therapy resulted in a decrease in the concentrations of bone resorption and bone formation markers compared with placebo; the decrease was maximal between 6 and 24. months. The effect of lasofoxifene 0.5. mg/d was similar to that of lasofoxifene 0.25. mg/d. The decrease in bone ALP was less than the decreases in CTX, osteocalcin, and PINP. Lasofoxifene therapy 0.5. mg/d resulted in BTM-defined response rates for CTX (decrease in concentration from baseline > 60{\%}), PINP (> 50{\%}), and bone ALP (> 30{\%}) of 35{\%}, 45{\%}, and 43{\%} of women at month 12, respectively, compared with placebo responses of 4{\%}, 4{\%}, and 7{\%}. In contrast, the increase in BMD took longer (50{\%} responded after 36. months of lasofoxifene 0.5. mg/d) and was not as specific (15{\%} of placebo group responded). Bone density change was weakly inversely correlated with change in the concentrations of BTMs. BTMs may prove useful in the monitoring of the response to lasofoxifene treatment for women with postmenopausal osteoporosis early in the course of treatment.",
keywords = "Bone turnover marker, Clinical trial, Osteoporosis, Treatment",
author = "Richard Eastell and Reid, {David M.} and Slobodan Vukicevic and Ensrud, {Kristine E.} and LaCroix, {Andrea Z.} and Thompson, {John R.} and Thompson, {David D.} and Cummings, {Steven R.}",
year = "2012",
month = "5",
day = "1",
doi = "10.1016/j.bone.2012.02.004",
language = "English",
volume = "50",
pages = "1135--1140",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Effects of 3years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis

AU - Eastell, Richard

AU - Reid, David M.

AU - Vukicevic, Slobodan

AU - Ensrud, Kristine E.

AU - LaCroix, Andrea Z.

AU - Thompson, John R.

AU - Thompson, David D.

AU - Cummings, Steven R.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - The aims of this study were to describe the changes in bone turnover markers (BTMs) in response to lasofoxifene therapy; to describe the changes in BTMs in the individual; and to examine the relationships between BTM levels on treatment and treatment outcomes. Women (n= 1126) aged 59-80. years with femoral neck or spine bone mineral density T-scores ≤-2.5 were randomized to lasofoxifene 0.25. mg/d, 0.5. mg/d, or placebo for 5. years. We measured serum C-telopeptide of type I collagen (CTX) and serum procollagen I N-propeptide (PINP), osteocalcin, and bone alkaline phosphatase (ALP) at baseline and at 1, 3, 6, 12, 24, and 36. months. Lasofoxifene therapy resulted in a decrease in the concentrations of bone resorption and bone formation markers compared with placebo; the decrease was maximal between 6 and 24. months. The effect of lasofoxifene 0.5. mg/d was similar to that of lasofoxifene 0.25. mg/d. The decrease in bone ALP was less than the decreases in CTX, osteocalcin, and PINP. Lasofoxifene therapy 0.5. mg/d resulted in BTM-defined response rates for CTX (decrease in concentration from baseline > 60%), PINP (> 50%), and bone ALP (> 30%) of 35%, 45%, and 43% of women at month 12, respectively, compared with placebo responses of 4%, 4%, and 7%. In contrast, the increase in BMD took longer (50% responded after 36. months of lasofoxifene 0.5. mg/d) and was not as specific (15% of placebo group responded). Bone density change was weakly inversely correlated with change in the concentrations of BTMs. BTMs may prove useful in the monitoring of the response to lasofoxifene treatment for women with postmenopausal osteoporosis early in the course of treatment.

AB - The aims of this study were to describe the changes in bone turnover markers (BTMs) in response to lasofoxifene therapy; to describe the changes in BTMs in the individual; and to examine the relationships between BTM levels on treatment and treatment outcomes. Women (n= 1126) aged 59-80. years with femoral neck or spine bone mineral density T-scores ≤-2.5 were randomized to lasofoxifene 0.25. mg/d, 0.5. mg/d, or placebo for 5. years. We measured serum C-telopeptide of type I collagen (CTX) and serum procollagen I N-propeptide (PINP), osteocalcin, and bone alkaline phosphatase (ALP) at baseline and at 1, 3, 6, 12, 24, and 36. months. Lasofoxifene therapy resulted in a decrease in the concentrations of bone resorption and bone formation markers compared with placebo; the decrease was maximal between 6 and 24. months. The effect of lasofoxifene 0.5. mg/d was similar to that of lasofoxifene 0.25. mg/d. The decrease in bone ALP was less than the decreases in CTX, osteocalcin, and PINP. Lasofoxifene therapy 0.5. mg/d resulted in BTM-defined response rates for CTX (decrease in concentration from baseline > 60%), PINP (> 50%), and bone ALP (> 30%) of 35%, 45%, and 43% of women at month 12, respectively, compared with placebo responses of 4%, 4%, and 7%. In contrast, the increase in BMD took longer (50% responded after 36. months of lasofoxifene 0.5. mg/d) and was not as specific (15% of placebo group responded). Bone density change was weakly inversely correlated with change in the concentrations of BTMs. BTMs may prove useful in the monitoring of the response to lasofoxifene treatment for women with postmenopausal osteoporosis early in the course of treatment.

KW - Bone turnover marker

KW - Clinical trial

KW - Osteoporosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84859322830&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2012.02.004

DO - 10.1016/j.bone.2012.02.004

M3 - Article

VL - 50

SP - 1135

EP - 1140

JO - Bone

JF - Bone

SN - 8756-3282

IS - 5

ER -